Curis
CRIS
#10981
Rank
A$0.96 M
Marketcap
A$0.50
Share price
-17.89%
Change (1 day)
-81.35%
Change (1 year)

Revenue for Curis (CRIS)

Revenue in 2026 (TTM): A$10.68 Million

According to Curis's latest financial reports the company's current revenue (TTM ) is A$10.08 Million. In 2025 the company made a revenue of A$14.09 Million a decrease over the revenue in the year 2024 that were of A$17.53 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Curis from 2001 to 2026

Annual revenue

Year Revenue Change
2026 (TTM) A$10.68 M-24.23%
2025 A$14.09 M-19.61%
2024 A$17.53 M19.21%
2023 A$14.71 M-1.48%
2022 A$14.93 M1.66%
2021 A$14.68 M4.24%
2020 A$14.09 M-1.38%
2019 A$14.28 M-3.47%
2018 A$14.8 M16.75%
2017 A$12.67 M21.41%
2016 A$10.44 M-3.45%
2015 A$10.81 M-10.08%
2014 A$12.02 M-28.49%
2013 A$16.81 M2.98%
2012 A$16.33 M13.43%
2011 A$14.39 M-8.59%
2010 A$15.75 M64.72%
2009 A$9.56 M-19.37%
2008 A$11.85 M-36.74%
2007 A$18.74 M-1.06%
2006 A$18.94 M21.71%
2005 A$15.56 M143.24%
2004 A$6.39 M-56.94%
2003 A$14.86 M-54.46%
2002 A$32.64 M1433.25%
2001 A$2.12 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Pfizer
PFE
A$90.43 B 896,317.95%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
A$69.24 B 686,336.36%๐Ÿ‡บ๐Ÿ‡ธ USA
Spectrum Pharmaceuticals
SPPI
A$36.74 M 264.28%๐Ÿ‡บ๐Ÿ‡ธ USA
Exelixis
EXEL
A$3.39 B 33,532.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Celldex Therapeutics
CLDX
A$1.23 M-87.74%๐Ÿ‡บ๐Ÿ‡ธ USA
Cel-Sci
CVM
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Emergent BioSolutions
EBS
A$0.92 B 9,043.42%๐Ÿ‡บ๐Ÿ‡ธ USA